We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Role of Mitochondria in Non Severe Asthma (MITASTHME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00808730
Recruitment Status : Completed
First Posted : December 16, 2008
Last Update Posted : February 17, 2010
Information provided by:
University Hospital, Bordeaux

Brief Summary:
Asthma is a frequent disease characterized by bronchial hyperresponsiveness, inflammation and remodelling. Bronchial remodelling is an abnormal repair process that contributes to the development of poorly reversible airway narrowing. It can appear very early in the evolution of the disease and involves an increased mass of bronchial smooth muscle (BSM). The mechanism of such an increase has been related with an increase in smooth muscle cell proliferation. Recently, we have demonstrated that, BSM increased proliferation is induced by an enhanced mitochondrial biogenesis in severe asthma (T. Trian et al. J Exp Med 2007). The objective of this study is to investigate the role of smooth muscle cell mitochondria in non severe asthma

Condition or disease Intervention/treatment Phase
Asthma Procedure: fiberoptic fibroscopy Not Applicable

Detailed Description:

Bronchial remodelling mainly involves an increased mass of bronchial smooth muscle (BSM), which is related with an increase proliferation of BSM cells. Recently, using BSM cells obtained from severe asthmatics, we have demonstrated that such an increase proliferation was induced by an activation cascade involving an abnormal calcium entry, and the subsequent activation of Calmodulin-kinase IV, PGC-1alpha, NRF-1 and mt-TFA leading to an increase mitochondrial biogenesis (T. Trian et al, J Exp Med 2007). The objective of this study is to investigate the role of BSM cell mitochondria in non severe asthma.

For this purpose, 30 non severe asthmatic adult patients (>18 yr) will be prospectively recruited from the "CHU de Bordeaux" according to the Global Initiative for Asthma (GINA) guidelines. Inclusion visit will include written informed consent, asthma control questionnaire, clinical examination, lung function testing (i.e. arterial gas, exhaled NO, plethysmography), prick tests, chest X Ray and blood sample for total IgE levels. Bronchial specimens will be obtained from all subjects by fiberoptic bronchoscopy. BSM remodelling will be evaluated by morphological analysis. Patients will be divided into 2 groups according to the presence or the absence of BSM remodelling. Using BSM cell culture, the role of mitochondria will be analyzed by electronic microscopy, confocal microscopy, immunoblotting, RT-PCR and oxygraphy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Role of Mitochondria in Human Bronchial Smooth Muscle Remodeling in Non Severe Asthma
Study Start Date : February 2009
Actual Primary Completion Date : November 2009
Actual Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma

Arm Intervention/treatment
Experimental: 1
fiberoptic fibroscopy
Procedure: fiberoptic fibroscopy
Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment

Primary Outcome Measures :
  1. BSM mitochondrial biogenesis assessed by the number of mitochondrial sections using electron microscopy, the porin content using western blot, and mitochondrial oxygen consumption evaluated by oxygraphy. [ Time Frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment ]

Secondary Outcome Measures :
  1. BSM remodelling assessed by optic microscopy and immunohistochemistry (using anti-alpha smooth muscle actin antibody). [ Time Frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment ]
  2. Transcription factors involved in mitochondrial biogenesis assessed by quantitative RT-PCR and western blot. [ Time Frame: One bronchial fiberoptic fibroscopy within 15 days after the enrolment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female aged more than 18 years
  • Diagnosis of intermittent asthma, mild persistent asthma or moderate persistent according to ATS criteria
  • Forced expiratory volume in one second > 60% predicted
  • Written informed consent

Exclusion Criteria:

  • Smoker or former smoker (tobacco or cannabis)
  • Adults protected by law
  • Subjects not affiliated with social security
  • Subjects during exclusion relative to another protocol or for which the annual maximum allowance of 3800 euros has been reached
  • Subject with any co-morbidity (except chronic rhinitis, chronic sinusitis nasal polyps or gastro-oesophageal reflux)
  • Asthma exacerbation within 6 weeks before enrolment
  • Infections of the upper airway within 3 months before enrolment
  • Chronic viral infections (hepatitis, HIV)
  • Pregnancy or breastfeeding
  • Contraindications to bronchoscopy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00808730

Layout table for location information
University Hospital Bordeaux, Hôpital Haut-Lévêque
Pessac, France, 33604
Sponsors and Collaborators
University Hospital, Bordeaux
Layout table for investigator information
Principal Investigator: Pierre-Olivier GIRODET, MCU-PH University Hospital Bordeaux / Département de Pharmacologie, CIC - Université Victor Segalen Bordeaux 2
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jean-Pierre LEROY / Clinical Research and Innovation Director, University Hospital, Bordeaux
ClinicalTrials.gov Identifier: NCT00808730    
Other Study ID Numbers: CHUBX 2008/29
First Posted: December 16, 2008    Key Record Dates
Last Update Posted: February 17, 2010
Last Verified: February 2010
Keywords provided by University Hospital, Bordeaux:
Asthma, airway remodelling, smooth muscle, mitochondria
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases